| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Reduced mortality after allogeneic hematopoietic-cell transplantation.
|
N Engl J Med
|
2010
|
7.20
|
|
2
|
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.
|
Blood
|
2008
|
2.39
|
|
3
|
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
2.32
|
|
4
|
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).
|
Semin Liver Dis
|
2002
|
2.17
|
|
5
|
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.
|
Blood
|
2006
|
1.95
|
|
6
|
A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.
|
Blood
|
2007
|
1.66
|
|
7
|
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
|
Blood
|
2003
|
1.59
|
|
8
|
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
|
Blood
|
2002
|
1.49
|
|
9
|
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.
|
Blood
|
2003
|
1.45
|
|
10
|
Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors.
|
Kidney Int
|
2005
|
1.35
|
|
11
|
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
|
Biol Blood Marrow Transplant
|
2010
|
1.34
|
|
12
|
Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
|
Biol Blood Marrow Transplant
|
2007
|
1.23
|
|
13
|
Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation.
|
Hepatology
|
2005
|
1.22
|
|
14
|
trans fatty acids and systemic inflammation in heart failure.
|
Am J Clin Nutr
|
2004
|
1.17
|
|
15
|
Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.
|
Clin J Am Soc Nephrol
|
2009
|
1.15
|
|
16
|
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.
|
Dig Dis Sci
|
2009
|
1.15
|
|
17
|
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
|
Blood
|
2002
|
1.11
|
|
18
|
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.
|
Biol Blood Marrow Transplant
|
2006
|
1.08
|
|
19
|
Cyclophosphamide metabolism is affected by azole antifungals.
|
Blood
|
2003
|
1.08
|
|
20
|
Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.
|
Clin Gastroenterol Hepatol
|
2007
|
1.05
|
|
21
|
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.03
|
|
22
|
Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease.
|
Nat Genet
|
2006
|
1.03
|
|
23
|
National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.
|
Biol Blood Marrow Transplant
|
2011
|
1.01
|
|
24
|
National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.
|
Biol Blood Marrow Transplant
|
2012
|
1.01
|
|
25
|
Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.
|
Int J Hematol
|
2013
|
0.96
|
|
26
|
Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach.
|
Clin Cancer Res
|
2006
|
0.93
|
|
27
|
A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.92
|
|
28
|
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
|
Biol Blood Marrow Transplant
|
2013
|
0.90
|
|
29
|
Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation.
|
Semin Hematol
|
2012
|
0.89
|
|
30
|
Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
|
Biol Blood Marrow Transplant
|
2011
|
0.88
|
|
31
|
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
Am J Cardiol
|
2005
|
0.88
|
|
32
|
Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure.
|
Am J Cardiol
|
2005
|
0.86
|
|
33
|
Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
|
Biol Blood Marrow Transplant
|
2009
|
0.86
|
|
34
|
Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
35
|
Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard.
|
Clin Pharmacol Ther
|
2004
|
0.85
|
|
36
|
In patients with heart failure elevated soluble TNF-receptor 1 is associated with higher risk of depression.
|
J Card Fail
|
2007
|
0.82
|
|
37
|
Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases.
|
Am J Surg Pathol
|
2015
|
0.81
|
|
38
|
Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale.
|
Blood
|
2002
|
0.80
|
|
39
|
Supportive care.
|
Hematology Am Soc Hematol Educ Program
|
2004
|
0.79
|
|
40
|
Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation.
|
Blood
|
2004
|
0.78
|
|
41
|
A simulation-based comparison of two methods for determining relaxation rates from relaxometry images.
|
Magn Reson Imaging
|
2011
|
0.77
|
|
42
|
Crohn disease: remissions but no cure.
|
Blood
|
2010
|
0.75
|
|
43
|
Hepatitis C virus and allogeneic stem cell transplantation still matters!
|
Haematologica
|
2009
|
0.75
|
|
44
|
Gallstones in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up.
|
J Pediatr Hematol Oncol
|
2014
|
0.75
|
|
45
|
Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.
|
Int J Hematol
|
2015
|
0.75
|